Transfer of Specificity for Human Immunodeficiency Virus Type 1 into Primary Human T Lymphocytes by Introduction of T-Cell Receptor Genes

ABSTRACT The introduction of genes encoding T-cell receptor (TCR) chains specific for human immunodeficiency virus into T cells of infected patients represents a means to quantitatively and qualitatively improve immunity to the virus. Our results demonstrate that the high level of TCR expression required for physiologic functioning can be reproducibly achieved with retroviral vectors encoding full-length unmodified TCR chains under the control of a strong internal constitutive phosphoglycerate kinase promoter.

[1]  S. Riddell,et al.  HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. , 2000, The Journal of clinical investigation.

[2]  A. Cooke,et al.  Triggering a Second T Cell Receptor on Diabetogenic T Cells Can Prevent Induction of Diabetes , 1999, The Journal of experimental medicine.

[3]  S. Rosenberg,et al.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.

[4]  P. Debré,et al.  Gene therapy approaches to HIV-infection: immunological strategies: use of T bodies and universal receptors to redirect cytolytic T-cells. , 1999, Frontiers in bioscience : a journal and virtual library.

[5]  L. Weinberger,et al.  Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.

[6]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[7]  R. Germain,et al.  The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. , 1999, Annual review of immunology.

[8]  S. Riddell,et al.  In vivo migration and function of transferred HIV-1-specific cytotoxic T cells , 1999, Nature Medicine.

[9]  J. Levy,et al.  Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. , 1998, Blood.

[10]  L. Pease,et al.  A retroviral vector that directs simultaneous expression of alpha and beta T cell receptor genes. , 1998, Human gene therapy.

[11]  M A Nowak,et al.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.

[12]  B. Walker,et al.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes , 1998, Nature.

[13]  Mark M. Davis,et al.  LIGAND RECOGNITION BY T CELL RECEPTORS , 1998 .

[14]  Z Reich,et al.  Ligand recognition by alpha beta T cell receptors. , 1998, Annual review of immunology.

[15]  M. McElrath,et al.  Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. , 1997, The New England journal of medicine.

[16]  B. Walker,et al.  Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Bartz,et al.  Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein. , 1997, Methods.

[18]  Martin A. Nowak,et al.  Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS , 1997, Nature Medicine.

[19]  Gotch Fm,et al.  New observations on cellular immune responses to HIV and T-cell epitopes. , 1997 .

[20]  S. Rowland-Jones,et al.  Role of cellular immunity in protection against HIV infection. , 1997, Advances in immunology.

[21]  J. Safrit,et al.  New observations on cellular immune responses to HIV and T-cell epitopes. , 1997, AIDS.

[22]  S. Riddell,et al.  Cytomegalovirus selectively blocks antigen processing and presentation of its immediate–early gene product , 1996, Nature.

[23]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[24]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[25]  H. Whittle,et al.  HIV‐2-specific cytotoxic T‐lymphocyte activity is inversely related to proviral load , 1995, AIDS.

[26]  H. Schuitemaker,et al.  Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics , 1995, The Journal of experimental medicine.

[27]  S. Rosenberg,et al.  Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. , 1995, Cancer research.

[28]  S. Riddell,et al.  Principles for adoptive T cell therapy of human viral diseases. , 1995, Annual review of immunology.

[29]  E. Kawasaki,et al.  A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Dull,et al.  Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors , 1994 .

[31]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[32]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[33]  T. Dull,et al.  Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. , 1994, Blood.

[34]  P. S. Kim,et al.  Peptide ‘Velcro’: Design of a heterodimeric coiled coil , 1993, Current Biology.

[35]  S. Riddell,et al.  CD8+ cytotoxic T cell therapy of cytomegalovirus and HIV infection. , 1993, Current opinion in immunology.

[36]  J. McKeating,et al.  Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization. , 1993, AIDS research and human retroviruses.

[37]  X. Jin,et al.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr virus in late disease , 1993, The Journal of experimental medicine.

[38]  Daniel G. Miller,et al.  Use of retroviral vectors for gene transfer and expression. , 1993, Methods in enzymology.

[39]  C. Griscelli,et al.  Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus‐1‐infected mothers , 1992, European journal of immunology.

[40]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[41]  S. Riddell,et al.  The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. , 1990, Journal of immunological methods.

[42]  M. Baseler,et al.  Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population. , 1990, Journal of immunology.

[43]  M. McBurney,et al.  Cloning and expression of the mouse pgk-1 gene and the nucleotide sequence of its promoter. , 1987, Gene.